I. López-Oreja

Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia

E. Giné, A. López-Guillermo, E. Campo, 2022, Hematological oncology.

Network-Based Drug Discovery Identifies Statins as a Repurposing Agent to Improve Activity of Current Therapies in Chronic Lymphocytic Leukemia.

E. Campo, D. Colomer, J. Delgado, 2020 .

Roles and mechanisms of alternative splicing in cancer — implications for care

J. Valcárcel, S. Bonnal, Irene López-Oreja, 2020, Nature Reviews Clinical Oncology.

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets

D. Colomer, M. López-Guerra, Irene López-Oreja, 2021, Cancers.

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

E. Campo, D. Colomer, J. Delgado, 2020, Scientific Reports.

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia

J. Valcárcel, M. Aymerich, D. Colomer, 2023, Life Science Alliance.

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation

S. Beà, M. Aymerich, D. Colomer, 2023, Leukemia.

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia

P. Jares, S. Beà, D. Colomer, 2023, HemaSphere.